Human EGFR-L858R/T790M/C797S Stable Cell Line-Ba/F3

The EGFR-L858R, T790M, and C797S mutations are pivotal genetic alterations identified in the development of resistance to EGFR-targeted therapies in non-small cell lung cancer (NSCLC) patients. EGFR-L858R, discovered in 2004, is a common activating mutation associated with NSCLC, leading to constitutive EGFR activation and tumor proliferation. Subsequently, the emergence of the T790M mutation, first identified in 2005, confers resistance to EGFR tyrosine kinase inhibitors (TKIs) by sterically hindering drug binding. C797S, discovered in 2013, represents a tertiary mutation that arises following treatment with third-generation EGFR TKIs, rendering them ineffective. In response to these discoveries, human EGFR-L858R/T790M/C797S stable cell lines, such as Ba/F3, have been developed as preclinical models to investigate drug resistance mechanisms and evaluate novel therapeutic strategies. These cell lines, engineered to harbor specific EGFR mutations, recapitulate the clinical scenario of acquired resistance to EGFR-targeted therapies, offering valuable insights into the underlying molecular mechanisms. The establishment of these models has significantly contributed to advancing our understanding of resistance mechanisms and facilitating the development of more effective treatment approaches for NSCLC patients.